SCHEMBL19008538

SCHEMBL19008538

CC(C)(C)c1cccc2[nH]c(N)nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 5/20 0.47
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MASP2 O00187 1/20 0.44
ALDH1A1 P00352 1/20 0.44
AOC3 Q16853 1/20 0.44
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KIF11 P52732 1/20 0.42
CDK5 Q00535 6/20 0.41
CDK5R1 Q15078 6/20 0.41
ULK1 O75385 1/20 0.40
CDK7 P50613 1/20 0.40
PRKCE Q02156 1/20 0.40
CAMK2G Q13555 1/20 0.40
DYRK1A Q13627 1/20 0.40
RPS6KA1 Q15418 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17276051 0.86 MEN1 (0.50) NUDT1MEN1KMT2AMASP2ALDH1A1
SCHEMBL19000985 0.80 L3MBTL1 (0.47) MEN1KMT2AALDH1A1POLBGAA
SCHEMBL13672552 0.80 PARP1 (0.50) MEN1KMT2AALDH1A1POLBGAA
SCHEMBL30291834 0.79 MEN1 (0.58) NUDT1MEN1KMT2AMASP2ALDH1A1
SCHEMBL3287778 0.79 MEN1 (0.58) NUDT1MEN1KMT2AMASP2ALDH1A1
SCHEMBL9305996 0.79 KIF11 (0.42) MEN1KMT2AALDH1A1POLBGAA
SCHEMBL9306197 0.79 KIF11 (0.42) MEN1KMT2AALDH1A1POLBGAA
SCHEMBL22599976 0.77 MGAM (0.48) GAA
SCHEMBL11835594 0.76 MEN1 (0.64) MEN1KMT2AALDH1A1POLBGAA
SCHEMBL727228 0.76 MGAM (0.53) NUDT1MEN1KMT2AMASP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9839642-B2 Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-9839642-B2 Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-12-12 US disclosed
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-06-22 US disclosed
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173035-A1 BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS MGAM, CMBL, PEPD NUDT1 3449/4885MEN1 1335/4885KMT2A 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.